Analysis of acetylcholinesterase inhibitors: Bioanalysis, degradation and metabolism

Biomedical Chromatography

Volumn 25, Issue 1, 2011, Pages 278-299

  Azevedo Marques, Lygia ^a   Giera, Martin ^a   Lingeman, Henk ^a   Niessen, Wilfried MA ^a  

^a VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

AChE inhibitors; Alzheimer's disease; Bioanalysis; LC MS; Metabolism; Stability

Indexed keywords

BIOMOLECULES; CEREBROSPINAL FLUID; MASS SPECTROMETRY; METABOLITES; NEURODEGENERATIVE DISEASES;

ACETYLCHOLINESTERASE INHIBITORS; ALZHEIMER; ALZHEIMERS DISEASE; ANALYSIS IN PLASMA; BIOANALYSIS; BIOLOGICAL MATRIXES; BIOLOGICAL SAMPLES; LC/MS; SECOND GENERATION; ULTRAVIOLET FLUORESCENCE;

METABOLISM;

1 BENZYL 4 (5,6 DIMETHOXY 1 OXOINDAN)METHYL PYRIDINIUM BROMIDE; 1 BENZYL 4 [(5,6 DIMETHOXY 1 INDANONE) 2 YL]METHYLPIPERIDIN 2 ENE; 1 HYDROXY TACRINE; 1,3 DIHYDROXY TACRINE; 2 (4 PIPERIDINYLMETHYL) 5,6 DIMETHOXY 1 INDANONE; 2 (4 PYRIDYLMETHYL) 5,6 DIMETHOXY 1 INDANONE; 2 HYDROXY TACRINE; 4 HYDROXY TACRINE; 7 HYDROXY TACRINE; CHOLINESTERASE INHIBITOR; DONEPEZIL; EPIGALANTAMINE; ESERINE BLUE; ESERINE BROWN; ESEROLINE; GALANTAMINE; GALANTAMINONE; HUPERZINE A; N DESMETHYL GALANTAMINE; N OXIDE GALANTAMINE; NAP 226 90; NAP 229 60; O DESMETHYL GALANTAMINE; PHOTOHUPERZINE A; PHYSOSTIGMINE; PHYSOSTIGMINE DERIVATIVE; RIVASTIGMINE; RUBRESERINE; TACRINE; TACRINE DERIVATIVE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; DEMENTIA; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DECOMPOSITION; DRUG DEGRADATION; DRUG DETERMINATION; DRUG EFFICACY; DRUG EXCRETION; DRUG GLUCURONIDATION; DRUG HALF LIFE; DRUG INTOXICATION; DRUG METABOLISM; DRUG STABILITY; DRUG STRUCTURE; DRUG TISSUE LEVEL; GLAUCOMA; HUMAN; NONHUMAN; REVIEW; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT;

EID: 78650669103     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.1573     Document Type: Review

References (116)

1. Albert A and Gledhill WJ. Improved synthesis of aminoacridines, Part IV. Substituted 5-aminoacridines. Journal of the Society of Chemical Industry 1945; 64: 169-172.
2. Apostolou C, Dotsikas Y, Kousoulos C and Loukas YL. Quantitative determination of donepezil in human plasma by liquid chromatography/tandem mass spectrometry employing an automated liquid-liquid extraction based on 96-well format plates. Application to a bioequivalence study. Journal of Chromatography B 2007; 848: 239-244.
3. Asakawa Y, Ozawa C, Osada K, Kaneko S and Asakawa N. Reduction of carry-over in column-switching HPLC/MS system with automated system washing procedure for highly sensitive direct analysis of donepezil in dog plasma. Journal of Pharmaceutical and Biomedical Analysis 2007; 43: 683-690.
4. Ashani Y, Peggins JO and Doctor BP. Mechanism of inhibition of cholinesterases by Huperzine-A. Biochemical and Biophysical Research Communications 1992; 184: 719-726.
5. Auterhoff H and Hamacher H. Die farbreaktionen des eserins. Archiv Der Pharmazie Und Berichte Der Deutschen Pharmazeutichen Gesselschaft 1967; 300: 849.
6. Aymard G, Cayre-Castel M, Fernandez C, Lacomblez L and Diquet B. High-performance liquid chromatography with ultraviolet and fluorimetric detection for the simultaneous determination of tacrine, nimodipine, and their respective metabolites in the plasma of patients with Alzheimer's disease. Therapeutic Drug Monitoring 1998; 20: 422-429.
7. Bakshi M and Singh S. Development of validated stability-indicating assay methods-critical review. Journal of Pharmaceutical and Biomedical Analysis 2002; 28: 1011-1040.
8. Bao D, Thanabal V and Pool WF. Determination of tacrine metabolites in microsomal incubate by high performance liquid chromatography-nuclear magnetic resonance/mass spectrometry with a column trapping system. Journal of Pharmaceutical and Biomedical Analysis 2002; 28: 23-30.
9. Berkov S, Bastida J, Viladomat F and Codina C. Analysis of galanthamine-type alkaloids by capillary gas chromatography-mass spectrometry in plants. Phytochemical Analysis 2008; 19: 285-293.
10. Bhatt J, Subbaiah G, Kambli S, Shah B, Nigam S, Patel M, Saxena A, Baliga A, Parekh H and Yadav G. A rapid and sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the estimation of rivastigmine in human plasma. Journal of Chromatography B 2007; 852: 115-121.
11. Bickel U, Thomsen T, Fisher JP, Weber W and Kewitz H. Galanthamine: pharmacokinetics, tissue distribution and cholinesterase inhibition in brain of mice. Neuropharmacology 1991; 30: 447-454.
12. Brodie RR, Chasseaud LF and Robbins AD. Determination of physostigmine in plasma by high-performance liquid chromatography. Journal of Chromatography 1987; 415: 423-431.
13. Chang JH, Kang HU, Jung IH and Cho CG. Total synthesis of (+/-)-galanthamine via a C3-selective Stille coupling and IMDA cycloaddition cascade of 3, 5-dibromo-2-pyrone. Organic Letters 2010; 12: 2016-2018.
14. Chien RL and Burgi DS. Field amplified sample injection in high-performance capillary electrophoresis. Journal of Chromatography 1991; 559: 141-152.
15. Chollet D, Castella E, Anderegg G, Arnera V and Hadler D. Therapeutic drug monitoring of tacrine: simple and fast high-performance liquid chromatography assay method for its determination in human plasma. Therapeutic Drug Monitoring 2000; 22: 225-229.
16. Claessens HA, van Thiel M, Westra P and Soeterboek AM. High-performance liquid chromatographic determination of galanthamine, a long-acting anticholinesterase drug, in serum, urine and bile. Journal of Chromatography 1983; 275: 345-353.
17. Coelho Filho J and Birks J. Physostigmine for dementia due to Alzheimer's disease. Cochrane Database of Systematic Reviews 2001; issue 2, no. CD001499; doi: 10.1002/14651858
18. de Jong CF, Derks RJ, Bruyneel B, Niessen W and Irth H. High-performance liquid chromatography-mass spectrometry-based acetylcholinesterase assay for the screening of inhibitors in natural extracts. Journal of Chromatography A 2006; 1112: 303-310.
19. Dworacek B and Ruprecht J. Physostigmine: short history and its impact on anaesthesiology of present days. International Congress Series 2002; 1242: 6.
20. Ekman E, Lindstrom B and Roxin P. Determination of tacrine and its 1-hydroxy metabolite in plasma using column liquid chromatography with ultraviolet detection. Journal of Chromatography 1989; 494: 397-402.
21. Elsayed NM, Ryabik JR, Ferraris S, Wheeler CR and Korte DW, Jr. Determination of physostigmine in plasma by high-performance liquid chromatography and fluorescence detection. Analytical Biochemistry 1989; 177: 207-211.
22. Enz A, Chappuis A and Dattler A. A simple, rapid and sensitive method for simultaneous determination of rivastigmine and its major metabolite NAP 226-90 in rat brain and plasma by reversed-phase liquid chromatography coupled to electrospray ionization mass spectrometry. Biochemical Chromatography 2004; 18: 160-166.
23. Frankfort SV, Ouwehand M, van Maanen MJ, Rosing H, Tulner LR and Beijnen JH. A simple and sensitive assay for the quantitative analysis of rivastigmine and its metabolite NAP 226-90 in human EDTA plasma using coupled liquid chromatography and tandem mass spectrometry. Rapid Communications in Mass Spectrometry 2006; 20: 3330-3336.
24. Garcia GE, Hicks RP, Skanchy D, MooradDoctor DR, Doctor BP and Ved HS. Identification and characterization of the major huperzine A metabolite in rat blood. Journal of Analytical Toxicology 2004; 28: 379-383.
25. Gauthier S and Poirier J. Current and future management of Alzheimer's disease. Alzheimer's and Dementia 2008; 4: S48-S50.
26. Giacobini E. Invited review: Cholinesterase inhibitors for Alzheimer's disease therapy: from tacrine to future applications. Neurochemistry International 1998; 32: 413-419.
27. Hadwiger ME, Telting-Diaz M and Lunte CE. Liquid chromatographic determination of tacrine and its metabolites in rat bile microdialysates. Journal of Chromatography B 1994; 655: 235-241.
28. Haginaka J and Chikako S. Determination of enantiomers of 1-benzyl-4-[(5, 6-dimethoxy-1-indanon)-2-yl]methylpiperidine hydrochloride (E20E20), a centrally acting acetylcholine esterase inhibitor, in plasma by liquid chromatography with fluorometric detection. Journal of Chromatography 1992; 577: 95-102.
29. Hameda AB, Taborsky P, Pena-Mendez EM and Havel J. Matrix-assisted laser desorption/ionization mass spectrometry (MALDI TOF MS) study of huperzine A, a natural anti-Alzheimer's disease product, its derivatization and its detection by highly sensitive laser induced fluorescence (LIF). Talanta 2007; 72: 780-784.
30. Hansen LL, Larsen JT and Brosen K. Determination of tacrine and its metabolites in human plasma and urine by high-performance liquid chromatography and fluorescence detection. Journal of Chromatography B 1998; 712: 183-191.
31. Haudrechy A, Chassaing C, Riche C and Langlois Y. A formal synthesis of (+)-huperzine A. Tetrahedron 2000; 56: 3181-3187.
32. Haughey DB, A. MC, Collus MS, Brown RR, Siedlik PH, Balogh L and Klockowski PM. Simultaneous determination of tacrine and 1-hydroxy-, 2-hydroxy-, and 4-hydroxytacrine in human plasma by high performance liquid chromatography with fluorescence detection. Journal of Pharmaceutical Sciences 1994; 83: 1582-1585.
33. Hoffmann M and Hock C. Alzheimer's disease: antidementive drugs. International Encyclopedia of the Social and Behavioral Sciences 2004; 418-423.
34. Hossain M. Estimation of the absolute bioavailability of rivastigmine in patients with mild to moderate dementia of the Alzheimer's type. Clinical Pharmacokinetics 2002; 41: 225-234.
35. Hsieh YH, Yang YH, Yeh HH, Lin PC and Chen SH. Simultaneous determination of galantamine, rivastigmine and NAP 226-90 in plasma by MEKC and its application in Alzheimer's disease. Electrophoresis 2009; 30: 644-653.
36. Hsu RS, DiLeo EM and Chesson SM. High-performance liquid chromatography for the determination of tacrine and its metabolites in plasma. Journal of Chromatography 1990a; 530: 170-176.
37. Hsu RS, Shutske GM, Dileo EM, Chesson SM, Linville AR and Allen RC. Identification of the urinary metabolites of tacrine in the rat. Drug Metabolism and Disposition 1990b; 18: 779-783.
38. ICH. (Q5B) Quality of Biotechnological Products: Stability Testing of Biotechnological/Biological Products. International Conference on Harmonization: Geneva, November 1995. Available from: .
39. ICH. (Q1B) Stability Testing: Photostability Testing of New Drug Substances and Products. International Conference on Harmonization, Geneva, November 1996. Available from: .
40. ICH. (Q6A) Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances. International Conference on Harmonization, Geneva, October 1999. Available from: .
41. ICH. (Q1A-R2) Stability Testing of New Drug Substances and Products. International Conference on Harmonization, Geneva, February 2003. Available from:
42. Isaksson K and Kissinger PT. Metabolism of physostigmine in mouse liver microsomal incubations studied by liquid chromatography with dual-electrode amperometric detection. Journal of Chromatography 1987; 419: 165-175.
43. Jiang Y, Zhang Y and Zhang ZR. Simultaneous determination of N-butyramide-tacrine and tacrine in mouse plasma and brain homogenate by high-performance liquid chromatography with a simple gradient solvent system. Journal of Chromatography B 2003; 791: 285-290.
44. Kafkala S, Matthaiou S, Alexaki P, Abatzis M, Bartseliotis A and Katsiabani M. New gradient high-performance liquid chromatography method for determination of donepezil hydrochloride assay and impurities content in oral pharmaceutical formulation. Journal of Chromatography A 2008; 1189: 392-397.
45. Karthik A, Sundarajan G, Surulivrlrajan M, Ranjithkumar A and Kamat SB. Fluorimetric determination of rivastigmine in rat plasma by reverse phase high performance liquid chromatographic method. Application to a pharmacokinetic study. Arzneimittelforschung 2008; 58: 205-210.
46. Kawahara M, Nishida A and Nakagawa M. An efficient synthesis of optically active physostigmine from tryptophan via alkylative cyclization. Organic Letters 2000; 2: 675-678.
47. Lawrence GD and Yatim N. Extraction of physostigmine from biologic fluids and analysis by liquid chromatography with electrochemical detection. Journal of Pharmacological Methods 1990; 24: 137-143.
48. Lee IYC, Jung MH, Lee HW and Yang JY. Synthesis of huperzine intermediates via Mn(III)-mediated radical cyclization. Tetrahedron Letters 2002; 43: 2407-2409.
49. Lee L, Hossain M, Wang Y and Sedek G. Absorption of rivastigmine from different regions of the gastrointestinal tract in humans. The Journal of Clinical Pharmacology 2004; 44: 599-604.
50. Leonard AK, Sileno AP, MacEvilly C, Foerder CA, Quay SC and Costantino HR. Development of a novel high-concentration galantamine formulation suitable for intranasal delivery. Journal of Pharmaceutical Sciences 2005; 94: 1736-1746.
51. Li C, Du F, Yu C, Xu X, Zheng J, Xu F and Zhu D. A sensitive method for the determination of the novel cholinesterase inhibitor ZT-1 and its active metabolite huperzine A in rat blood using liquid chromatography/tandem mass spectrometry. Rapid Communications in Mass Spectrometry 2004; 18: 651-656.
52. Li W, Li J and Hu Q. Determination of huperzine A in human plasma by liquid chromatography-electrospray tandem mass spectrometry: application to a bioequivalence study on Chinese volunteers. Biomedical Chromatography 2008; 22: 354-360.
53. Li YX, Jiang XH, Lan K and Wang L. Simple determination of huperzine A in human plasma by liquid chromatographic-tandem mass spectrometric method. Biomedical Chromatography 2007; 21: 15-20.
54. Liang YQ and Tang XC. Comparative effects of huperzine A, donepezil and rivastigmine on cortical acetylcholine level and acetylcholinesterase activity in rats. Neurosciences Letters 2004; 361: 56-59.
55. Ma X and Gang DR. In vitro production of huperzine A, a promising drug candidate for Alzheimer's disease. Phytochemistry 2008; 69: 2022-2028.
56. Malakova J, Nobilis M, Svoboda Z, Lisa M, Holcapek M, Kvetina J, Klimes J and Palicka V. High-performance liquid chromatographic method with UV photodiode-array, fluorescence and mass spectrometric detection for simultaneous determination of galantamine and its phase I metabolites in biological samples. Journal of Chromatography B 2007; 853: 265-274.
57. Mamelak M. Alzheimer's disease, oxidative stress and gammahydroxybutyrate. Neurobiology of Aging 2007; 28: 1340-1360.
58. Mannens GS, Snel CA, Hendrickx J, Verhaeghe T, Le Jeune L, Bode W, van Beijsterveldt L, Lavrijsen K, Leempoels J, Van Osselaer N, Van Peer A and Meuldermans W. The metabolism and excretion of galantamine in rats, dogs, and humans. Drug Metabolism and Disposition 2002; 30: 553-563.
59. Marques LA, Kool J, de Kanter F, Lingeman H, Niessen W and Irth H. Production and on-line acetylcholinesterase bioactivity profiling of chemical and biological degradation products of tacrine. Journal of Pharmaceutical and Biomedical Analysis 2010a; 53: 609-616.
60. Marques LA, Giera M, de Kanter FJJ, Niessen WMA, Lingeman H and Irth H. Photohuperzine A-A new photoisomer of huperzine A: structure elucidation, formation kinetics and activity assessment. Journal of Pharmaceutical and Biomedical Analysis 2010b; 52: 190-194.
61. Maslow K. Alzheimer's disease facts and figures. Alzheimer's and Dementia 2008; 4: 110-113.
62. Matsui K, Mishima M, Nagai Y, Yuzuriha T and Yoshimura T. Absorption, distribution, metabolism, and excretion of donepezil (Aricept) after a single oral administration to Rat. Drug Metabolism and Disposition 1999a; 27: 1406-1414.
63. Matsui K, Oda Y, Nakata H and Yoshimura T. Simultaneous determination of donepezil (aricept) enantiomers in human plasma by liquid chromatography-electrospray tandem mass spectrometry. Journal of Chromatography B 1999b; 729: 147-155.
64. Miller RL and Verma PS. A radioimmunoassay for physostigmine in biological fluids. Journal of Pharmaceutical and Biomedical Analysis 1989; 7: 955-963.
65. Mukai C, Yoshida T, Sorimachi M and Odani A. Co2(CO)8-catalyzed intramolecular hetero-Pauson-Khand reaction of alkynecarbodiimide: synthesis of (+/-)-physostigmine. Organic Letters 2006; 8: 83-86.
66. Mustazza C, Borioni A, Del Giudice MR, Gatta F, Ferretti R, Meneguz A, Volpe MT and Lorenzini P. Synthesis and cholinesterase activity of phenylcarbamates related to Rivastigmine, a therapeutic agent for Alzheimer's disease. European Journal of Medicinal Chemistry 2002; 37: 91-109.
67. Nakagawa M and Kawahara M. A concise synthesis of physostigmine from skatole and activated aziridine via alkylative cyclization. Organic Letters 2000; 2: 953-955.
68. 30 column. Journal of Pharmaceutical and Biomedical Analysis 2006; 41: 201-206.
69. Niphade N, Mali A, Jagtap K, Ojha RC, Vankawala PJ and Mathad VT. An improved and efficient process for the production of donepezil hydrochloride: substitution of sodium hydroxide for n-butyl lithium via phase transfer catalysis. Organic Process Research and Development 2008; 12: 731-735.
70. Nirogi VSR, Kandikere VN, Mudigonda K and Maurya S. Quantitative determination of galantamine in human plasma by sensitive liquid chromatography-tandem mass spectrometry using loratadine as an internal standard. Journal of Chromatographic Science 2007; 45: 97-103.
71. Pan JY, Wang Q, Shao Q, Cheng YY and Qu HB. Development and validation of a column-switching LC-ESI-MS assay for determination of huperzine A in rat plasma and cerebrospinal fluid. Chromatographia 2009; 69: 445-451.
72. Pappa H, Farru R, Vilanova PO, Palacios M and Pizzorno MT. A new HPLC method to determine Donepezil hydrochloride in tablets. Journal of Pharmaceutical and Biomedical Analysis 2002; 27: 177-182.
73. Patel BN, Sharma N, Sanyal M and Shrivastav PS. Quantitation of donepezil and its active metabolite 6-O-desmethyl donepezil in human plasma by a selective and sensitive liquid chromatography-tandem mass spectrometric method. Analytica Chimica Acta 2008; 629: 145-157.
74. Polinsky RJ. Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Clinical Therapeutics 1998; 20: 634-647.
75. Pommier F and Frigola R. Quantitative determination of rivastigmine and its major metabolite in human plasma by liquid chromatography with atmospheric pressure chemical ionization tandem mass spectrometry. Journal of Chromatography B 2003; 784: 301-313.
76. Poobrasert O and Cordell GA. Blue degradation products of rubreserine. Journal of Natural Products 1997; 60: 578-580.
77. Pool WF, Reily MD, Bjorge SM and Woolf TF. Metabolic disposition of the cognition activator tacrine in rats, dogs, and humans. Species comparisons. Drug Metabolism and Disposition 1997; 25: 590-597.
78. Qian L and Ji R. A total synthesis of (±)-huperzine A. Tetrahedron Letters 1989; 30: 2089-2090.
79. Racchi M, Mazzucchelli M, Porrello E, Lanni C and Govoni S. Acetylcholinesterase inhibitors: novel activities of old molecules. Pharmacological Research 2004; 50: 441-451.
80. Radwan MA, Abdine HH, Al-Quadeb BT, Aboul-Enein HY and Nakashima K. Stereoslective HPLC assay of donepezil enantiomers with UV detection and its application to phamacokinetics in rats. Journal of Chromatography B 2006; 830: 114-119.
81. Rao BM, Srinivasu MK, Kumar KP, Bhradwaj N, Ravi R, Mohakhud PK, Reddy GO and Kumar RR. A stability indicating LC method for Rivastigmine hydrogen tartrate. Journal of Pharmaceutical and Biomedical Analysis 2005; 37: 57-63.
82. Rubnov S, Levy D and Schneider H. Liquid chromatographic analysis of physostigmine salicylate and its degradation products. Journal of Pharmaceutical and Biomedical Analysis 1999; 18: 939-945.
83. Salway AH. Researches on the constitution of physostigmine Part I. Journal of the Chemical Society 1912; 101: 978-989.
84. Satcharoen V, McLean NJ, Kemp SC, Camp NP and Brown RCD. Stereocontrolled synthesis of (-)-galanthamine. Organic Letters 2007; 9: 1867-1869.
85. Sathyan G, Ritschel WA and Hussain AS. Transdermal delivery of tacrine. 1. Identification of a suitable delivery vehicle. International Journal of Pharmaceuticals 1995; 114: 75-83.
86. Scriabine A. The 9th International Conference on Alzheimer's Disease and Related Disorders. Philadelphia, PA. July 17-22, 2004. CNS Drug Reviews 2004; 10: 270-280.
87. Sha Y, Deng C, Liu Z, Huang T, Yang B and Duan G. Headspace solid-phase microextraction and capillary gas chromatographic-mass spectrometric determination of rivastigmine in canine plasma samples. Journal of Chromatography B 2004; 806: 271-276.
88. Shah HJ, Kundlik ML, Pandya A, Prajapati S, Subbaiah G, Patel CN, Patel DM and Suhagia BN. A rapid and specific approach for direct measurement of donepezil concentration in human plasma by LC-MS/MS employing solid-phase extraction. Biomedical Chromatography 2009; 23: 141-151.
89. Somani SM and Khalique A. Determination of physostigmine in plasma and brain by HPLC. Journal of Analytical Toxicology 1985; 9: 71-75.
90. Sugimoto H. The new approach in development of anti-Alzheimer's disease drugs via the cholinergic hypothesis. Chemico-biological Interactions 2008; 175: 204-208.
91. Sugimoto H, Iimura Y, Yamanishi Y and Yamatsu K. Synthesis and antiacetylcholinesterase activity of 1-benzyl-4-[(5, 6-dimethoxy-1-indanon-2-yl)methyl]piperidine hydrochloride (E2020) and related-compounds. Bioorganic and Medicinal Chemistry Letters 1992; 2: 871-876.
92. Sugimoto H, Ogura H, Arai Y, Limura Y and Yamanishi Y. Research and development of donepezil hydrochloride, a new type of acetylcholinesterase inhibitor. Japanese Journal of Pharmacology 2002; 89: 7-20.
93. Summers WK, Majovski LV, Marsh GM, Tachiki K and Kling A. Oral tetrahydroaminoacridine in long-term treatment of senile dementia, alzheimer type. New England Journal of Medicine 1986; 315: 1241-1245.
94. Tencheva J, Yamboliev I and Zhivkova Z. Reversed-phase liquid chromatography for the determination of galanthamine and its metabolites in human plasma and urine. Journal of Chromatography 1987; 421: 396-400.
95. Terabe S. Micellar electrokinetic chromatography for high-performance analytical separation. Chemical Record 2008; 8: 291-301.
96. 14C-donepezil in healthy volunteers: a single-dose study. British Journal of Clinical Pharmacology 1998; 46(suppl. 1): 19-24.
97. Toribio A, Delannay E, Richard B, Ple K, Zeches-Hanrot M, Nuzillard JM and Renault JH. Preparative isolation of huperzines A and B from Huperzia serrata by displacement centrifugal partition chromatography. Journal of Chromatography 2007; 1140: 101-106.
98. Trost BM and Zhang Y. Molybdenum-catalyzed asymmetric allylation of 3-alkyloxindoles: application to the formal total synthesis of (-)-physostigmine. Journal of the American Chemical Society 2006; 128: 4590-4591.
99. Unni LK, Hannant ME, Becker RE and Giacobini E. Determination of physostigmine in plasma and cerebrospinal fluid by liquid chromatography with electrochemical detection. Clinical Chemistry 1989; 35: 292-295.
100. Verhaeghe T, Diels L, de Vries R, De Meulder M and de Jong J. Development and validation of a liquid chromatographic-tandem mass spectrometric method for the determination of galantamine in human heparinised plasma. Journal of Chromatography B 2003; 789: 337-346.
101. Visky D, Jimidar I, Van Ael W, Vennekens T, Redlich D and De Smet M. Capillary electrophoresis-mass spectrometry in impurity profiling of pharmaceutical products. Electrophoresis 2005; 26: 1541-1549.
102. Wang R, Yan H and Tang XC. Progress in studies of huperzine A, a natural cholinesterase inhibitor from Chinese herbal medicine. Acta Pharmacologica Sinica 2006; 27: 1-26.
103. Wang Y, Chu D, Gu J, Fawcett JP, Wu Y and Liu W. Liquid chromatographic-tandem mass spectrometric method for the quantitation of huperzine A in dog plasma. Journal of Chromatography B 2004; 803: 375-378.
104. Wei G, Xiao S, Lu R and Liu C. Simultaneous determination of ZT-1 and its metabolite Huperzine A in plasma by high-performance liquid chromatography with ultraviolet detection. Journal of Cromatography B 2006; 830: 120-125.
105. Whelpton R and Moore T. Sensitive liquid chromatographic method for physostigmine in biological fluids using dual-electrode electrochemical detection. Journal of Chromatography 1985; 341: 361-371.
106. Wilson B, Samanta MK, Santhi K, Kumar KP, Paramakrishnan N and Suresh B. Targeted delivery of tacrine into the brain with polysorbate 80-coated poly(n-butylcyanoacrylate) nanoparticles. Europeran Journal of Pharmaceutics and Biopharmaceutics 2008; 70: 75-84.
107. Wu QQ and Gu YH. Quantification of huperzine A in Huperzia serrata by HPLC-UV and identification of the major constituents in its alkaloid extracts by HPLC-DAD-MS-MS. Journal of Pharmaceutical and Biomedical Analysis 2006; 40: 993-998.
108. Xiaochao M, Haixue W, Jian X, Zhang T and Zenghong T. Identification of cytocrome P450 1A2 as enzyme involved in the microsomal metabolism of huperzine A. European Journal of Pharmacology 2003; 461: 89-92.
109. Xie Z, Liao Q, Xu X, Yao M, Wan J and Liu D. Rapid and sensitive determination of donepezil in human plasma by liquid chromatography/tandem mass spectrometry: application to a phamacokinetic study. Rapid Communications in Mass Spectrometry 2006; 20: 3193-3198.
110. Yamreudeewong W, Dolence EK and Pahl D. Stability of donepezil in an extemporaneously prepared oral liquid. Journal of Pharmacy Practice 2006; 19: 282.
111. Yasui-Furukori N, Furuya R, Takahata T and Tateishi T. Determination of donepezil, an acetylcholinesterase inhibitor, in human plasma by high-performance liquid chromatography with ultraviolet absorbance detection. Journal of Chromatography B 2002; 768: 261-265.
112. Ye J, Zeng S, Zhang W and Chen G. Ion-pair reverse-phase high performance liquid chromatography method for determination of Huperzine-A in beagle dog serum. Journal of Chromatography B 2005; 817: 187-191.
113. Yeh H, Yang Y, Ko J and Chen S. Sensitive analysis of donepezil in plasma by capillary electrophoresis combining on-column field-amplified sample stacking and its application in Alzheimer's disease. Electrophoresis 2008; 29: 3649-3657.
114. Yue P, Tao T, Zhao Y, Ren J and Chai X. Determination of huperzine A in rat plasma by high-performance liquid chromatography with a fluorescence detector. Journal of Pharmaceutical and Biomedical Analysis 2007a; 44: 309-312.
115. Yue P, Tao T, Zhao Y, Ren J and Chai X. Huperzine A in rat plasma and CSF following intranasal administration. International Journal of Pharmaceuticals 2007b; 337: 127-132.
116. Zhao B, Moochhala SM, Chaw CS and Yang YY. Simple liquid chromatographic method for the determination of physostigmine and its metabolite eseroline in rat plasma: application to a pharmacokinetic study. Journal of Chromatography B 2003; 784: 323-329.